67. Polycystic kidney disease Clinical trials / Disease details
Clinical trials : 221 / Drugs : 212 - (DrugBank : 55) / Drug target genes : 40 - Drug target pathways : 151
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000012865 | 2014/06/30 | 01/03/2014 | Ursodeoxycholic acid for polycystic liver disease | Ursodeoxycholic acid for polycystic liver disease - UDCA for PLD | polycystic liver disease, polycystic kidney disease | UDCA 600mg/day standard treatment | Nephrology Center, Toranomon Hospital | NULL | Complete: follow-up complete | Not applicable | Not applicable | Male and Female | 100 | Not selected | Japan |
| 2 | NCT02021110 (ClinicalTrials.gov) | December 2013 | 12/12/2013 | Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease | An International, Multicenter, Randomized Controlled Clinical Trial Assessing the Efficacy of Ursodeoxycholic Acid as a Volume Reducing Treatment in Symptomatic Polycystic Liver Disease | Polycystic Liver Disease;Polycystic Kidney, Autosomal Dominant | Drug: Ursodeoxycholic Acid | Radboud University | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Completed | 18 Years | 80 Years | All | 34 | Phase 2 | Netherlands;Spain |
| 3 | EUCTR2013-003207-19-NL (EUCTR) | 29/11/2013 | 08/08/2013 | Trial to investigate the effect of ursodeoxycholic acid as a treatment of symptoms in polycystic liver disease: the CURSOR-trial | An international, multicenter, randomized controlled clinical trial assessing the efficacy of Ursodeoxycholic acid as a volume reducing treatment for symptomatic polycystic livers - The CURSOR trial | Patients suffering from symptomatic polycystic liver disease (PLD) with underlying diagnosis of isolated polycystic liver disease (PCLD) or autosomal dominant kidney disease (ADPKD);Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: URSOCHOL 300 | Radboud University Nijmegen Medical Center | NULL | Not Recruiting | Female: yes Male: yes | 34 | Phase 4 | Spain;Netherlands |